Oxford BioMedica Annouces Board Changes
Oxford BioMedica, a leading gene therapy company, announced today changes to the composition of its Board of Directors. With effect from 28 August 2008, Dr Mike McDonald, Chief Executive Officer, has left the Board of Oxford BioMedica.With immediate effect, John Dawson, who was appointed as Non-Executive Director on 1 August 2008, will take the position of Acting Chief Executive Officer.Commenting on these developments, Professor Alan Kingsman, Oxford BioMedica's Chairman, said: 'We would like to thank Dr McDonald for his major contributions to the TroVax and ProSavin programmes. His expertise in drug development programmes and his clinical leadership have been much valued. We wish him well for the future. We welcome John Dawson to the role of Acting Chief Executive Officer, and we look forward to making a permanent appointment in due course.'
For the original article please visit, here.